Trial site
Henan Provincial Cancer Hospital
Zhengzhou, 450008, ChinaNot linked to an institution yet
- 10running trials
- 2closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 1/25 trials
- Phase 2/31 trial
- Status
- Recruiting7 trials
- Not yet recruiting3 trials
- Completed2 trials
- Lead sponsor
- Ascentage Pharma Group Inc.1 trial
- Beijing Continent Pharmaceutical Co, Ltd.1 trial
- BioNTech SE1 trial
- Daiichi Sankyo1 trial
- Gilead Sciences1 trial
- and 7 more
Running trials
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Ning Li, Doctor
Recruiting
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
NCT07388680· Phase 2/3· Beijing Continent Pharmaceutical Co, Ltd.· Source
Contact: Hong Ge
Recruiting
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
NCT07207070· Phase 3· Risen (Suzhou) Pharma Tech Co., Ltd.· Source
Contact: Binghe Xu, Ph.D
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456· Phase 3· Ascentage Pharma Group Inc.· Source
Contact: Keshu Zhou, M.D., Ph.D.
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· Phase 3· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Source
Contact: Min Yan
Recruiting
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
NCT07231068· Phase 1/2· Henan Genuine Biotech Co., Ltd.· Source
Contact: Junling Li
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error